Real-world data show that Enhertu (fam-trastuzumab deruxtecan-nxki) was tolerated as well in the community setting, where ...

While Enhertu (trastuzumab deruxtecan, T-DXd) is an established treatment for patients with HER2-low metastatic breast cancer ...

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 ...

Fewer older women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer are undergoing routine ...

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.

Inflammation has been linked to symptoms that many survivors experience, including fatigue, pain, cognitive difficulties and mood changes. The idea behind this research is that if we can reduce ...

Resilience plays a key role in helping patients adjust after cancer treatment ends, according to Frank Penedo, professor of ...

Long-term results from a phase 2 study presented at the 27th European Congress on Gynaecological Oncology (ESGO 2026) in Hong ...

De-escalation to survivorship can provoke anxiety and “untethered” feelings despite favorable prognosis, reflecting loss of ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...